Centrivive Clinical Experience

58 double blind, randomized, controlled clinical trials involving 8,800 patients confirm -

First 90-Days Death and Dependency
Significant reduction in composite outcome of Death and Dependency.
Modified Rankin Scale (MRS)
Barthel Index (BI)
National Institute of Health Stroke Scale (NIHSS)
Large Cerebral Artery Stenosis
Progressive Cerebral Infarction (PCI)
Post Stroke Syndrome
Vascular Dementia
No Serious Adverse Effects Reported

Dosage used

CENTRIVIVE Capsules 200 mg three times daily taken 15 minutes before each meal. Can be started as early with t-NK/t-PA /mechanical intervention or within 24 h after intravenous thrombolysis or as a sequential therapy within 48-72 hours on AIS.

CENTRIVIVE is to be added to the existing protocol of treatments including anti-coagulants, anti-platelets, statins etc.

Duration of treatment

90 DAYS.

CENTRIVIVE does not have enough evidence in haemorrhagic stroke and should be used only in cases on Ischemic stroke.